自己免疫性肺胞タンパク症 (aPAP) における吸入モルグラモスチム ネブライザー溶液の臨床試験 (IMPALA-2)
自己免疫性肺胞タンパク症 (aPAP) の成人被験者における 1 日 1 回吸入モルグラモスチム ネブライザー溶液の無作為化二重盲検プラセボ対照臨床試験
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.
An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.
The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Dublin、アイルランド、DO4 T6F4
- St. Vincent's University Hospital
-
-
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University Of Arkansas For Medical Services
-
-
California
-
Los Angeles、California、アメリカ、90095
- UCLA David Geffen School of Medicine
-
-
Colorado
-
Denver、Colorado、アメリカ、80206
- National Jewish Health
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- University of Florida Health
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University
-
-
Illinois
-
Maywood、Illinois、アメリカ、60153
- Loyola University
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland Medical Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Washington University in St. Louis
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Raleigh、North Carolina、アメリカ、27610
- Wake Med Health & Hospital
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229-3039
- Cincinnati Children's Hospital Medical Center
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Perelman School of Medicine - Pulmonology
-
Pittsburgh、Pennsylvania、アメリカ、15213
- University of Pittsburgh
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- UT Southwestern Medical Center
-
-
-
-
London
-
London、London、イギリス、SW3 6NP
- Royal Brompton and Harefield NHS Foundation Trust
-
-
-
-
Lombardy
-
Pavia、Lombardy、イタリア、27100
- Fondazione IRCCS Policlinico San Matteo
-
-
-
-
Utrecht
-
Nieuwegein、Utrecht、オランダ、3435CM
- St Antonius Hospital
-
-
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア、2050
- Royal Prince Alfred Hospital
-
Westmead、New South Wales、オーストラリア、2145
- Westmead Hospital
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 4N1
- University of Calgary
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 4A6
- St Joseph's Healthcare Hamilton Research
-
-
Quebec
-
Québec、Quebec、カナダ、G1V 4G5
- University Institute of Cardiology and Respirology of Quebec
-
-
-
-
-
Athens、ギリシャ、12462
- Attikon University Hospital
-
-
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、08907
- Hospital Universitario de Bellvitge
-
-
-
-
Ankara
-
Ankara、Ankara、トルコ(Türkiye)、6010
- Health Sciences University Gulhane Training and Research Hospital
-
-
Istanbul
-
Istanbul、Istanbul、トルコ(Türkiye)、34020
- Yedikule Chest Disease and Surgery Training and Research Hospital
-
-
İzmir
-
Bornova、İzmir、トルコ(Türkiye)、35100
- Ege University Hospital - Department of Pulmonology
-
-
-
-
Baden-Wurttemberg
-
Heidelberg、Baden-Wurttemberg、ドイツ、69126
- Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
-
-
Bavaria
-
Muenchen-Gauting、Bavaria、ドイツ、82131
- Asklepios Fachkliniken Muenchen-Gauting
-
-
North Rhine-Westphalia
-
Essen、North Rhine-Westphalia、ドイツ、45239
- Ruhrlandklinik Westdeutsches Lungenzentrum
-
-
-
-
Auvergne-Rhône-Alpes
-
Bron、Auvergne-Rhône-Alpes、フランス、69500
- Hôpital Louis Pradel
-
-
Brittany Region
-
Rennes、Brittany Region、フランス、35033
- CHU Pontchaillou
-
-
-
-
Brussels Capital
-
Brussels、Brussels Capital、ベルギー、1070
- Hôpital Erasme
-
-
Vlaams Brabant
-
Leuven、Vlaams Brabant、ベルギー、3000
- UZ Leuven - Campus Gasthuisberg - Pneumologie
-
-
-
-
Lisbon District
-
Lisbon、Lisbon District、ポルトガル、1769-001
- Hospital Pulido Valente
-
-
Porto District
-
Porto、Porto District、ポルトガル、4200-319
- Hospital São João
-
-
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、ポーランド、01-138
- Instytut Gruzlicy i Chorob Pluc
-
-
-
-
Bucharest
-
Bucharest、Bucharest、ルーマニア、050159
- Institutul de Pneumoftiziologie "Marius Nasta"
-
-
-
-
-
Nagakute、日本、480-1195
- Aichi Medical University Hospital
-
-
Chiba
-
Chiba、Chiba、日本、260-8677
- Chiba University Hospital - Respiratory Medicine
-
-
Hokkaidô
-
Sapporo、Hokkaidô、日本、060-8648
- Hokkaido University Hospital
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、236-0051
- Kanagawa Cardiovascular and Respiratory Center
-
-
Kumamoto
-
Kumamoto、Kumamoto、日本、860-8556
- Kumamoto University Hospital
-
-
Miyagi
-
Sendai、Miyagi、日本、980-8574
- Tohoku University Hospital - Respiratory Tract Medicine
-
-
Osaka
-
Sakai、Osaka、日本、591-8555
- National Hospital Organization Kinki-Chuo Chest medical Center
-
-
Saitama
-
Saitama、Saitama、日本、330-8553
- Saitama Red Cross Hospital
-
-
Tokyo
-
Mitaka、Tokyo、日本、181-8611
- Kyorin University Hospital
-
-
-
-
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、03722
- Severance Hospital - Yonsei University Health System - Pulmonary
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).
-
A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.
-
History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.
-
A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.
-
Change in %DLCO adj of <15% points during the screening period.
-
Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).
-
Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.
-
Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.
-
Male or female
-
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
- Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
-
Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
-
Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.
Exclusion Criteria:
- Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
- Whole lung lavage (WLL) performed within 3 months prior to baseline.
- Requirement for WLL at screening or baseline.
- GM-CSF treatment within 6 months prior to baseline.
- Treatment with rituximab within 6 months prior to baseline.
- Treatment with plasmapheresis within 6 weeks prior to baseline.
- Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
- Previously randomized in this trial.
- History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
- Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
- Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
- History of, or present, myeloproliferative disease or leukemia.
- Apparent pre-existing concurrent pulmonary fibrosis.
- Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
- Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
- Physical disability or other condition that precludes safe and adequate exercise testing.
- Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
- Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
- For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Molgramostim
Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks |
Molgramostim 300 µg nebulizer solution
他の名前:
|
|
プラセボコンパレーター:Placebo
Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks |
Matching placebo nebulizer solution
他の名前:
|
|
実験的:Molgramostim Open-label Extension
Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks |
Molgramostim 300 µg nebulizer solution
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
時間枠:From Baseline to Week 24
|
As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). |
From Baseline to Week 24
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
時間枠:From Baseline to Week 48
|
As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange. |
From Baseline to Week 48
|
|
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
時間枠:From Baseline to Week 24
|
The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health. |
From Baseline to Week 24
|
|
Change From Baseline in SGRQ Activity Component Score to Week 24
時間枠:From Baseline to Week 24
|
The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity |
From Baseline to Week 24
|
|
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
時間枠:From Baseline to Week 24
|
As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity. |
From Baseline to Week 24
|
|
Change From Baseline in SGRQ Total Score to Week 48
時間枠:From Baseline to Week 48
|
The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health. |
From Baseline to Week 48
|
|
Change From Baseline in SGRQ Activity From Baseline to Week 48
時間枠:From Baseline to Week 48
|
The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity |
From Baseline to Week 48
|
|
Change From Baseline in EC, Expressed as Peak METs to Week 48
時間枠:From Baseline to Week 48
|
As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity. |
From Baseline to Week 48
|
|
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
時間枠:From Baseline to Week 24
|
A-aDO2 was used as an additional measure of gas exchange. |
From Baseline to Week 24
|
|
Number of Subjects With Serious and Non-serious Adverse Events
時間枠:From Baseline until End of Double-blind treatment (Week 48)
|
Assessment of the safety of molgramostim compared to placebo |
From Baseline until End of Double-blind treatment (Week 48)
|
|
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
時間枠:From Baseline until End of Double-blind treatment Week-48
|
Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline). |
From Baseline until End of Double-blind treatment Week-48
|
|
Changes in Forced Vital Capacity (FVC) %Predicted Normal
時間枠:From Baseline to Weeks 24 and 48
|
Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity. |
From Baseline to Weeks 24 and 48
|
|
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
時間枠:From Baseline to Weeks 24 and 48
|
FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function. |
From Baseline to Weeks 24 and 48
|
|
Change in QT Interval Corrected by Fridericia (QTcF)
時間枠:From Baseline to Weeks 4 and 24
|
Assessment of the safety of MOL compared to placebo |
From Baseline to Weeks 4 and 24
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Bruce Trapnell, MD、Children's Hospital Medical Center, Cincinnati
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- SAV006-05
- 2020-001263-85 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。